Targeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity

Authors

  • Gloria Ciniero PolitoBIOMedLab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Torino
  • Francesco Gentile University of Alberta, Faculty of Medicine & Dentistry, Edmonton, AB
  • Ahmed H. Elmenoufy University of Alberta, Faculty of Medicine & Dentistry, Edmonton, AB
  • Emeline Cros-Perrial Université Claude Bernard Lyon 1, Lyon
  • Frederick G. West University of Alberta, Faculty of Medicine & Dentistry, Edmonton, AB
  • Michael Weinfeld University of Alberta, Faculty of Medicine & Dentistry, Edmonton, AB
  • Marco A. Deriu PolitoBIOMedLab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Torino
  • Lars P. Jordheim Université Claude Bernard Lyon 1, Lyon
  • Jack A. Tuszynski PolitoBIOMedLab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Torino

DOI:

https://doi.org/10.4081/bse.164

Keywords:

Drug resistance, ERCC1-XPF, p53, cancer therapy

Abstract

New disruptors of the ERCC1-XPF interaction interaction have a synergistic effect with traditional NER inhibitors, in p53 positive cells. Furthermore, the synergy can be resumed in p53 negative cells upon reactivation of the TP53 gene.

Downloads

Download data is not yet available.

References

Downloads

Published

29-09-2021

Issue

Vol. 2 No. 1 (2021)

Section

Communications

License

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

How to Cite

Targeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity. (2021). Biomedical Science and Engineering, 2(1). https://doi.org/10.4081/bse.164